{
    "clinical_study": {
        "@rank": "132935", 
        "arm_group": [
            {
                "arm_group_label": "Vortioxetine 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "encapsulated tablets; 3 daily doses in each treatment period; orally"
            }, 
            {
                "arm_group_label": "Vortioxetine 20 mg", 
                "arm_group_type": "Experimental", 
                "description": "encapsulated tablets; 3 daily doses in each treatment period; orally"
            }, 
            {
                "arm_group_label": "Escitalopram 15 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "encapsulated tablets; 3 daily doses in each treatment period; orally"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "capsules; 3 daily doses in each treatment period; orally"
            }
        ], 
        "brief_summary": {
            "textblock": "To explore a neurophysiological marker (electroencephalography) of cognitive effect of\n      vortioxetine"
        }, 
        "brief_title": "Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects", 
        "condition": "Healthy Men", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject has a normal resting EEG at screening visit\n\n          -  The subject is able to perform tasks with an auditory stimulus\n\n          -  The subject is not visually impaired - normal prescription glasses are accepted\n\n          -  The subject has a normal circadian rhythm, defined as a person who usually wakes\n             between 6:00 and 9:00 a.m. and goes to sleep between 9:00 pm and midnight.\n\n        Exclusion Criteria:\n\n          -  The subject has worked shifts, including night duty, or has travelled across >3 time\n             zones <2 weeks prior to the first dose of IMP.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072278", 
            "org_study_id": "15835A", 
            "secondary_id": "2013-004015-53"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vortioxetine 10 mg", 
                "intervention_name": "Vortioxetine 10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vortioxetine 20 mg", 
                "intervention_name": "Vortioxetine 20 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Escitalopram 15 mg", 
                "intervention_name": "Escitalopram 15 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexetimide", 
                "Citalopram"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rennes", 
                    "country": "France", 
                    "zip": "35000"
                }, 
                "name": "FR801"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "official_title": "Interventional, Randomised, Double-blind, Placebo-controlled, Active Comparator, Four-way Crossover Electroencephalography Study Investigating the Effects of Vortioxetine (Lu AA21004) in Healthy Male Subjects", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Peak amplitude and latency of P300\nAUC of qEEG power spectral bands delta, theta, alpha, beta and gamma\nAUC of evoked gamma power spectral band\nPeak amplitude and latency of N200\nPeak amplitude and latency of error related negativity\nPeak amplitudes and latencies in the evoked responses during successful versus non-successful encoding in the verbal memory task between treatments", 
            "measure": "Battery of EEG measurements", 
            "safety_issue": "No", 
            "time_frame": "The EEG task battery will be conducted on Days -1 and starting 6 hours post-dose on Days 1 and 3 of each treatment period."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072278"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}